← Back to Search

Behavioural Intervention

Active Vibrotactile Coordinated Reset (vCR) for Dementia

N/A
Waitlist Available
Led By Peter Tass, MD PhD
Research Sponsored by Synergic Medical Technologies, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14months

Summary

This trial is testing a special glove that sends gentle vibrations to the fingertips to help Parkinson's disease patients. The goal is to offer a non-invasive alternative to medications and surgeries, which can have severe side effects or risks. The vibrations are believed to help the brain better control movement, potentially reducing symptoms. A wearable tremor suppression glove has been previously demonstrated to manage hand and finger tremor in Parkinson's disease patients.

Eligible Conditions
  • Dementia
  • Parkinson's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 14months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Movement Disorders Society Unified Parkinson's Disease Rating Scale Part 3
Secondary study objectives
Gait
Kinesia One motor evaluation
Levodopa equivalent daily dose (LEDD)
+8 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Active Vibrotactile Coordinated Reset (vCR)Active Control1 Intervention
Participants in this arm will receive active vCR stimulation.
Group II: Sham Vibrotactile Coordinated Reset (vCR)Placebo Group1 Intervention
Participants in this arm will receive sham vCR stimulation.

Find a Location

Who is running the clinical trial?

Stanford UniversityOTHER
2,467 Previous Clinical Trials
17,496,066 Total Patients Enrolled
12 Trials studying Dementia
2,656 Patients Enrolled for Dementia
Synergic Medical Technologies, Inc.Lead Sponsor
2 Previous Clinical Trials
60 Total Patients Enrolled
Peter Tass, MD PhDPrincipal InvestigatorStanford University
~9 spots leftby Nov 2025